CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$6.59 USD
+0.05 (0.76%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $6.52 -0.07 (-1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.59 USD
+0.05 (0.76%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $6.52 -0.07 (-1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -15.79% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 21.05% and 58.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
by Zacks Equity Research
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 36.17% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -42.86% and 6.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 163.83% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 18.75% and 9.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -2.42% and 3.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 13.85% and 19.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 1.59% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
CASI Pharma (CASI) has been struggling lately, but the selling pressure may be coming to an end soon.
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 44.44% and 16.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.